CROI 2012: Eric Lefebvre - Cenicriviroc

Eric A. Lefebvre, MD, Chief Medical Officer, Tobira Therapeutics.

Eric describes the phase IIb trial of Cenicriviroc, which will decide the single daily dose to move forward with into the Phase III trial. He also discusses the anti-inflammatory benefit of Cenicriviroc through the CCR-2 blocking function of this compound.

No comments:

Post a Comment